Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals has initiated a first-in-human Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of AT-587, an oral antiviral nucleotide analog targeting Hepatitis E Virus (HEV), which currently has no approved treatments. The trial is a randomized, double-blind, placebo-controlled dose escalation study in healt…